Goggins Eibhlin, Xie Yanjun, Huang Yi, Brantley Carson, Yao Junlan, Cechova Sylvia, Hossack John A, Okusa Mark D
Division of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States.
Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, United States.
Am J Physiol Renal Physiol. 2025 Aug 1;329(2):F234-F249. doi: 10.1152/ajprenal.00294.2024. Epub 2025 Jun 12.
Acute kidney injury (AKI) is a devastating condition with major complications including death and, in some cases, progression to chronic kidney disease (CKD). We have previously shown that pulsed ultrasound (pUS) can reduce kidney ischemia-reperfusion injury (IRI) by activating the cholinergic anti-inflammatory pathway. The efficacy of a spleen-targeted pUS regimen in AKI of other etiologies and its long-term impact are unclear. Using a new spleen-targeted US approach, pUS was delivered to male mice 24 h before folic acid (FA), lipopolysaccharide, or bilateral kidney IRI. Mice were monitored and assessed for markers of inflammation, renal function, and kidney fibrosis. When compared with sham, mice that received spleen-targeted pUS had reduced plasma TNFα and blood urea nitrogen (BUN) after sepsis-associated AKI, reduced plasma creatinine, and BUN after kidney IRI and reduced plasma creatinine, BUN, and kidney fibrosis after FA administration. pUS-treated mice displayed reduced myeloid cell infiltration to the kidneys after FA and IRI. In sham-treated mice, markers associated with ongoing maladaptive repair including , , and were increased on after FA in comparison with pUS-treated mice. These data demonstrate that pulsed ultrasound of the spleen is a novel, safe, and effective therapy for the prevention of AKI of multiple etiologies and the subsequent development of CKD. Findings from this study are critical for advancing human translation of ultrasound as a preventative measure for AKI and CKD. We developed a safe and effective pulsed ultrasound (pUS) protocol targeting the mouse spleen to block inflammation and reduce AKI of multiple etiologies. By using a model of the AKI to CKD transition, we demonstrated the long-term benefits of pUS. The findings of these studies will be used to advance the human translation of spleen-targeted US as a preventative measure for AKI and CKD.
急性肾损伤(AKI)是一种严重的病症,会引发包括死亡在内的重大并发症,在某些情况下还会进展为慢性肾脏病(CKD)。我们之前已经表明,脉冲超声(pUS)可通过激活胆碱能抗炎途径减轻肾脏缺血再灌注损伤(IRI)。针对脾脏的pUS方案在其他病因所致AKI中的疗效及其长期影响尚不清楚。采用一种新的靶向脾脏的超声方法,在给雄性小鼠注射叶酸(FA)、脂多糖或进行双侧肾脏IRI前24小时对其施加pUS。对小鼠进行监测,并评估炎症、肾功能和肾纤维化的标志物。与假手术组相比,接受靶向脾脏pUS的小鼠在脓毒症相关性AKI后血浆肿瘤坏死因子α(TNFα)和血尿素氮(BUN)降低,在肾脏IRI后血浆肌酐和BUN降低,在给予FA后血浆肌酐、BUN和肾纤维化降低。pUS治疗的小鼠在给予FA和IRI后,肾脏的髓样细胞浸润减少。在假手术治疗的小鼠中,与持续的适应性不良修复相关的标志物,包括 、 和 ,在给予FA后 与pUS治疗的小鼠相比有所增加。这些数据表明,脾脏脉冲超声是一种预防多种病因所致AKI及随后CKD发生的新型、安全且有效的疗法。本研究结果对于推动将超声作为AKI和CKD预防措施的人体转化应用至关重要。我们开发了一种安全有效的靶向小鼠脾脏的脉冲超声(pUS)方案,以阻断炎症并减轻多种病因所致的AKI。通过使用AKI向CKD转变的模型,我们证明了pUS的长期益处。这些研究结果将用于推动将靶向脾脏的超声作为AKI和CKD预防措施的人体转化应用。